Clinical effect of ⁸⁹SrCl₂ combined with zoledronic acid on treatment of transferable bone tumor

Objective: To explore the clinical effect of the radioactive nuclide strontium chloride (⁸⁹SrCl₂) and the association of ⁸⁹SrCl₂ and zoledronic acid in the treatment of transferable bone tumor. Methods: 43 patients with transferable bone tumor were divided into two groups randomly, 21 patients were treated with ⁸⁹SrCl₂, 22 patients used the association of ⁸⁹SrCl₂ and zoledronic acid. The curative effect of remission of bone ache, the bone metabolism of metastatic focus, the change of the quality of life, and the reaction of hematological toxicity after the treatment was observed. The χ² test was used in data analysis. Results: In the single item treatment group, the pain relief rate was 71.4%(15/21), the effective rate of bone metabolism of metastatic focus was 33.3% (7/21) and the effective rate of improving whole body Karnofsky Performance Status (KPS) score was 57.1%(12/21) after treatment. In the combined treatment group, the palliative rate was 95.5%(21/22), the effective rate of bone metabolism of metastatic focus was 54.5 % (12/22) and the effective rate of improving KPS score was 86.4% (19/22). There are statistically significant differences between the combined treatment group and the single treatment group in the pain relief rate and in terms of improvement in whole body KPS score (P < 0.05), and the hematological toxicities were 19.0% and 22.7% respectively (P > 0.05). Conclusion: The ⁸⁹SrCl₂ and zoledronic acid has an obvious curative effect in the treatment of transferable bone tumor, And then it is thought as safety and reliability. Combined treatment with ⁸⁹SrCl₂ and zoledronic acid is more effective than single treatment with ⁸⁹SrCl₂. (authors)